<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04159246</url>
  </required_header>
  <id_info>
    <org_study_id>s-5-2019</org_study_id>
    <nct_id>NCT04159246</nct_id>
  </id_info>
  <brief_title>Role OF OCT-A TO Detect Possible Retinal Vascular Complications of Sofosbuvir in Patients With Hepatitis C</brief_title>
  <official_title>Role OF OCT-A TO Detect Possible Retinal Vascular Complications of Sofosbuvir (Sovaldi) in Patients With Hepatitis C Virus Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mohamed Saad</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to prospectively evaluate the value of Optical coherence
      tomography angiography (OCT-A) for the of detection of suspected retinal complications With
      Sofosbuvir (Sovaldi) in Patients With Hepatitis C Virus Infection
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      During 3 months duration ( the treatment course duration) , Optical coherence tomography
      angiography (OCT-A) will be performed to 30 eyes of 30 patients with a documented diagnosis
      of chronic hepatitis C before and after receiving dual-therapy planning (Daclatasvir −
      Sofosbuvir (Sovaldi)) , normal renal functions And Rheumatoid factor tests , will undergo a
      comprehensive ophthalmic examination including:

        -  Manifest refraction

        -  Corrected distance visual acuity

        -  Anterior segment examination using slit lamp and tear film breakup time test

        -  Fundus examination

      Recent Optical coherence tomography angiography (OCT-A) will be performed to all patients
      before Treatment Administration.

      Examination will be performed using &quot;Optovue AngioVue®&quot; &quot;Optovue, Inc., Fremont, CA&quot;, which
      uses split-spectrum amplitude-decorrelation angiography algorithm, which minimizes motion
      noise. This system also allows quantitative analysis, since it provides numerical data about
      flow area and flow density maps.

      The patient will be examined before and after finishing the treatment course

      * Optical coherence tomography angiography (OCT-A) image acquisition OCT-A will be done for
      all patients who are instructed to focus on a fixation target. OCTA images are obtained using
      the &quot;RTVue XR Avanti (AngioVue; Optovue Inc, Fremont, California, USA)&quot; machine and the
      incorporated &quot;AngioVue OCT-A&quot; system. Algorithm used is Split-Spectrum Amplitude
      Decorrelation Algorithm (SSADA). The scans which will be included in the study are of high
      signal strength more than 0.7 and they will be carefully inspected for motion artifacts.
      Automatic segmentation of intraretinal layers will be done using the automated software of
      the machine (version 2016.2.0; Optovue Inc). Angio-retina scan sizes in this study will be 6
      X 6 mm for all eyes. Assessment of the macular vessel density will be done for superficial
      vascular layer, capillary plexus, deep capillary plexus and all retinal plexuses). Assessment
      of the foveal avascular zone on both superficial vascular layer (SVL) and deep capillary
      plexuses (DCP); including its size, perimeter and circularity (regularity) index. Circularity
      index is a measure of compactness of a shape relative to a circle. The circularity index of a
      circle is 1.0. Thus, a ratio closer to 0 indicates an irregular shape, and that closer to 1.0
      indicates a circular shape.

      All results will be in numerical values (percentage) to compare retinal vascularity before
      and after using the drug. Best corrected visual acuity (in values from o.o5 to 1.0) , dryness
      (in seconds) will be also measured before and after drug administration and it will be
      compared .
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 10, 2019</start_date>
  <completion_date type="Anticipated">November 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment percentage of change in macular vessels density using OCTA</measure>
    <time_frame>3 months</time_frame>
    <description>Evaluate the suspected retinal vascular complications With Sofosbuvir (Sovaldi) ) in Patients With Hepatitis C Virus Infection, All results will be in numerical values (percentage) to compare retinal vascularity before and after using the drug..</description>
  </primary_outcome>
  <primary_outcome>
    <measure>visual acuity changes with Sofosbuvir</measure>
    <time_frame>3 months</time_frame>
    <description>Comparing best corrected visual acuity (in values from o.o5 to 1.0) before and after drug administration .</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>amount of ocular dryness with Sofosbuvir using tear up breaking test</measure>
    <time_frame>3 months</time_frame>
    <description>Measuring amount of ocular dryness using Tear-up breaking test, dryness will be evaluated in seconds before and after drug administration and it will be compared .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Role of Optical coherence tomography angiography (OCTA) in detection early signs retinopathy depending on changes in vascular density</measure>
    <time_frame>3 months</time_frame>
    <description>Confirm the advantages of Optical coherence tomography angiography (OCT - A) in detection early signs retinopathy depending on changes in vascular density (evaluated as a percentage)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>amount of ocular dryness with Sofosbuvir using Schirmer's</measure>
    <time_frame>3 months</time_frame>
    <description>Measuring amount of ocular dryness using Tear-up breaking test, dryness will be evaluated in millimeters of wetness of schirmer's strips before and after drug administration and it will be compared .</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>HCV Infection</condition>
  <arm_group>
    <arm_group_label>Sovaldi group</arm_group_label>
    <description>patients with a documented diagnosis of chronic hepatitis C , normal renal functions And Rheumatoid factor tests (to exclude Purtscher like retinopathy as a rare presentation of cryoglobuinemia which considered one of extra hepatic manifestations of HCV)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Optical coherence tomography angiography</intervention_name>
    <description>Recent Optical coherence tomography angiography &quot;OCT-A&quot; will be performed to all patients before Treatment Administration.
Examination will be performed using Optovue AngioVue® &quot;Optovue, Inc., Fremont, CA&quot;, which uses split-spectrum amplitude-decorrelation angiography algorithm, which minimizes motion noise. This system also allows quantitative analysis, since it provides numerical data about flow area and flow density maps.
The patient will be examined before and after finishing the treatment course</description>
    <arm_group_label>Sovaldi group</arm_group_label>
    <other_name>OCTA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir (Sovaldi)</intervention_name>
    <description>Sofosbuvir (tradename Sovaldi) is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C , here it's used with Daclatasvir for 3 months</description>
    <arm_group_label>Sovaldi group</arm_group_label>
    <other_name>Sovaldi</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Convenience sample 30 eyes of 30 patients with a documented diagnosis of chronic hepatitis
        C
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 20 and 80 years.

          -  Patients with chronic hepatitis C enrolled for (Daclatasvir - Sofosbuvir (Sovaldi)) .

          -  Patients who have normal ocular and fundoscopic examination before the onset of
             treatment.

        Exclusion Criteria:

          -  Relapsed cases who have formerly taken the antiviral therapy (depending on the basis
             of medical record and filing system), or treated with interferon for any other cause .

          -  Patients with elevated renal functions or positive Rheumatoid factor (as a clue to
             diagnose Purtscher like retinopathy which is a rare presentation of cryoglobulinemia
             ,considered one of extra hepatic manifestations of HCV )
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Hany E Elmekewy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Magada S Abdelaziz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yomna A Abdelwahab, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mai I Mehrez, MD</last_name>
    <role>Study Chair</role>
    <affiliation>National Hepatology &amp; Tropical Medicine Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cairo University - Kasr Alainy</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Chebil A, Mammouri R, Abdallah MB, El Matri L. Purtscher-like Retinopathy as a Rare Presentation of Cryoglobulinemia. Middle East Afr J Ophthalmol. 2016 Apr-Jun;23(2):219-21. doi: 10.4103/0974-9233.177409.</citation>
    <PMID>27162457</PMID>
  </reference>
  <reference>
    <citation>Salman AG. Ocular Surface Changes With Sofosbuvir in Egyptian Patients With Hepatitis C Virus Infection. Cornea. 2016 Mar;35(3):323-8. doi: 10.1097/ICO.0000000000000736.</citation>
    <PMID>26764884</PMID>
  </reference>
  <reference>
    <citation>Manoharan N, Subramanian PS. A case of non-arteritic anterior ischemic optic neuropathy after completion of Harvoni therapy. Am J Ophthalmol Case Rep. 2017 Mar 8;6:55-57. doi: 10.1016/j.ajoc.2017.03.002. eCollection 2017 Jun.</citation>
    <PMID>29260058</PMID>
  </reference>
  <reference>
    <citation>Chin Loy K, Galaydh F, Shaikh S. Correction: Retinopathy and Uveitis Associated with Sofosbuvir Therapy for Chronic Hepatitis C Infection. Cureus. 2016 Jul 14;8(7):c3. doi: 10.7759/cureus.c3.</citation>
    <PMID>27610281</PMID>
  </reference>
  <reference>
    <citation>Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, Schultz M, Davis MN, Kayali Z, Reddy KR, Jacobson IM, Kowdley KV, Nyberg L, Subramanian GM, Hyland RH, Arterburn S, Jiang D, McNally J, Brainard D, Symonds WT, McHutchison JG, Sheikh AM, Younossi Z, Gane EJ. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013 May 16;368(20):1878-87. doi: 10.1056/NEJMoa1214853. Epub 2013 Apr 23.</citation>
    <PMID>23607594</PMID>
  </reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 1, 2019</study_first_submitted>
  <study_first_submitted_qc>November 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 12, 2019</study_first_posted>
  <last_update_submitted>November 7, 2019</last_update_submitted>
  <last_update_submitted_qc>November 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Mohamed Saad</investigator_full_name>
    <investigator_title>Resident of Ophthalmology , Cairo University - researcher</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sofosbuvir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All required non private data</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>30 November 2019</ipd_time_frame>
    <ipd_access_criteria>upon request of Any qualified and specialized Doctor or medical journal</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 15, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/46/NCT04159246/ICF_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 15, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/46/NCT04159246/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

